These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine. Ponticelli C; Tarantino A; Aroldi A; Sparacino V; Stefoni S; Citterio F; Duca L; Scolari MP; Calabrese S; Altieri P; Civati G; Cesana B Transplant Proc; 2003 May; 35(3 Suppl):62S-63S. PubMed ID: 12742469 [TBL] [Abstract][Full Text] [Related]
25. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800 [No Abstract] [Full Text] [Related]
26. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment. Engelbertink R; Smak Gregoor P; Hesse C; IJzermans J; Weimar W; van Gelder T Transplant Proc; 2002 Nov; 34(7):2983-4. PubMed ID: 12431677 [No Abstract] [Full Text] [Related]
27. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine. Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512 [TBL] [Abstract][Full Text] [Related]
28. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years. Gracida C; Melchor JL Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262 [No Abstract] [Full Text] [Related]
29. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients. Suhail SM; Vathsala A; Lou HX; Woo KT Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922 [No Abstract] [Full Text] [Related]
30. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Pham PT; Pham PC Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327 [TBL] [Abstract][Full Text] [Related]
36. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338 [No Abstract] [Full Text] [Related]
37. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Kuypers DR; Evenepoel P; Maes BD; Coosemans W; Pirenne J; Vanrenterghem YF Transplant Proc; 2002 Jun; 34(4):1164-70. PubMed ID: 12072305 [No Abstract] [Full Text] [Related]
38. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction. Islam MS; Francos GC; Dunn SR; Burke JF Transplant Proc; 1998 Aug; 30(5):2230-1. PubMed ID: 9723452 [No Abstract] [Full Text] [Related]
39. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335 [No Abstract] [Full Text] [Related]
40. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Kimball JA; Pescovitz MD; Book BK; Norman DJ Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]